News & Events about Arbutus Biopharma Corporation.
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified ...
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., ...
Ticker Report
2 months ago
Arbutus Biopharma (NASDAQ:ABUS Get Rating) had its price target reduced by HC Wainwright from $7.50 to $6.00 in a research report report published on Thursday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical companys stock. Separately, StockNews.com ...
Globe Newswire
2 months ago
Financially strong with a projected cash runway into thesecond quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year ...
Globe Newswire
4 months ago
WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Gaston Picchio, PhD, Chief ...